ライフサイエンスコーパス: tocilizumab

1 p=0.59 for tocilizumab plus methotrexate vs tocilizumab).

2 ials of remdesivir, sarilumab, selinexor, or tocilizumab.

3 ne the durability of remission and safety of tocilizumab.

4 ted with the interleukin-6 receptor antibody tocilizumab.

5 h the difference eliminated upon addition of tocilizumab.

6 onist anakinra and the IL-6 receptor blocker tocilizumab.

7 ter administration of off-label, single-dose tocilizumab.

8 rologic toxicities and CRS not responsive to tocilizumab.

9 tumor necrosis factor-alpha antagonists and tocilizumab.

10 SD) of 30.9 (15.9) months after switching to tocilizumab.

11 l as reveals a novel mechanism of action for tocilizumab.

12 ith the anti-interleukin-6 receptor antibody tocilizumab.

13 on of tumor cells in vitro as effectively as tocilizumab.

14 (7.4%) occurred that were felt unrelated to tocilizumab.

15 response, using the IL-6 receptor antagonist tocilizumab.

16 ance metrics after treatment initiation with tocilizumab.

17 nt after IL-6 receptor-directed therapy with tocilizumab.

18 tudies are needed to confirm the efficacy of tocilizumab.

19 nd alemtuzumab (anti-CD52), before receiving tocilizumab.

20 ent-year), occurred in patients who received tocilizumab.

21 eria for nonresponse were offered open-label tocilizumab.

22 ctions in temperature and CRP were seen post-tocilizumab.

23 n-6 (anti-IL-6) receptor monoclonal antibody tocilizumab.

24 gents, followed by abatacept, rituximab, and tocilizumab.

25 interleukin-6 receptor monoclonal antibody, tocilizumab.

26 those receiving monotherapy with 2 mg/kg of tocilizumab.

27 ocilizumab and 1419 (40.6%) not treated with tocilizumab.

28 zumab and 21 of 62 (34%) who did not receive tocilizumab.

29 ; 95% CI, 0.82-0.94) mortality compared with tocilizumab.

30 and two in the standard care group received tocilizumab.

31 n of uveitic macular edema than subcutaneous tocilizumab.

32 whose treatment did not include early use of tocilizumab.

33 8.4%) received baricitinib and 4,432 (41.6%) tocilizumab.

34 ercept, 50.0% with rituximab, and 20.0% with tocilizumab.

35 inhibitory monoclonal IL6 receptor antibody tocilizumab.

36 irements diminished over the first week post-tocilizumab.

37 plasma, hydroxychloroquine, steroids, and/or tocilizumab.

38 high-dose steroids, lopinavir/ritonavir, and tocilizumab.

39 eumonia patients received one 400 mg dose of tocilizumab.

40 k increased 1.7-fold with each 12-h delay to tocilizumab.

41 rituximab to 3.67% (CI, 1.69% to 7.88%) with tocilizumab.

42 G + rituximab +/- PLEX (plasma exchange) +/- tocilizumab.

43 hydroxychloroquine (71%), antibiotics (74%), tocilizumab (13%), and antivirals (14%).

44 ndomly assigned (1:1) to weekly subcutaneous tocilizumab 162 mg or placebo.

45 zithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%).

46 r necrosis factor-alpha antagonists [80%] or tocilizumab [20%]) and fulfilling American College of Rh

47 (5676 patients), rituximab (5444 patients), tocilizumab (2548 patients), or tofacitinib (1565 patien

48 that time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to control.

49 luding B-cell depletion, and who switched to tocilizumab (6-8 mg/kg of body weight per dose).

50 in the matched dataset (tocilizumab = 66; no tocilizumab = 66).

51 tients were included in the matched dataset (tocilizumab = 66; no tocilizumab = 66).

52 Questionnaire showed greater decreases with tocilizumab 8 mg/kg and 4 mg/kg (-144.1 and -128.4 units

53 ained on stable doses of DMARDs and received tocilizumab 8 mg/kg or placebo (control group) every 4 w

54 -modified Sharp score was 0.29 and 0.34 with tocilizumab 8 mg/kg plus MTX and 4 mg/kg plus MTX, respe

55 tandard care plus one or two doses of either tocilizumab (8 mg per kilogram of body weight intravenou

56 e standard care plus a single dose of either tocilizumab (8 mg per kilogram of body weight) or placeb

57 nit (ICU), were randomly assigned to receive tocilizumab (8 mg per kilogram of body weight), sariluma

58 were randomly assigned (1:1) to intravenous tocilizumab (8 mg/kg every 4 weeks) or oral azathioprine

59 Patients received tocilizumab (8 mg/kg or 4 mg/kg) or placebo every 4 week

60 herapeutic regimen with monthly infusions of tocilizumab (8 mg/kg) may increase efficacy.

61 Like tofacitinib, tocilizumab, a biologic targeting the IL-6 pathway, has

62 as subsequent IL-6 receptor blockade through tocilizumab, a complete and stable remission of symptoms

63 Blockade of IL6 signaling with tocilizumab, a drug approved by the Food and Drug Admini

64 ntation of a B-cell-anergizing therapy using tocilizumab, a humanized monoclonal antibody against the

65 y higher proportion of patients receiving IV tocilizumab achieved resolution of macular edema at 6 mo

66 Five attacks were associated with delayed tocilizumab administration (>/=40 days), and 6 attacks w

67 The duration between CRS onset and tocilizumab administration was associated with CV events

68 ated with mortality that did not change with tocilizumab administration.

69 Adalimumab, etanercept, infliximab and tocilizumab all showed statistically significant improve

70 A similar association was found for tocilizumab alone (OR, 0.18; 95% CI, 0.04-0.83; P = .03)

71 ies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or wit

72 The efficacy and safety of tocilizumab, an interleukin 6 receptor-alpha inhibitor,

73 3%) died, including 125 (28.9%) treated with tocilizumab and 1419 (40.6%) not treated with tocilizuma

74 rted in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocil

75 We enrolled 87 patients: 43 assigned to tocilizumab and 44 assigned to placebo.

76 tients, of whom 59 were randomly assigned to tocilizumab and 59 were randomly assigned to azathioprin

77 patients were included, of whom 78 received tocilizumab and 76 did not.

78 aimed to compare the safety and efficacy of tocilizumab and azathioprine in patients with highly rel

79 ication and immunomodulatory agents, such as tocilizumab and baricitinib, act to reduce a dysregulate

80 occurred in 6.7% and 4.3% of patients in the tocilizumab and control groups, respectively, and seriou

81 penia occurred in 3.7% of patients receiving tocilizumab and none of the patients in the control grou

82 Tocilizumab and rituximab have been shown to lead to imp

83 Tocilizumab and rituximab may also be of benefit in refr

84 the contention that early intervention with tocilizumab and/or corticosteroids in subjects with earl

85 We report that early intervention with tocilizumab and/or corticosteroids may reduce the freque

86 n doubled the numbers of subjects dosed with tocilizumab and/or corticosteroids, there was no apparen

87 -methotrexate) was tapered and stopped, then tocilizumab (and placebo-tocilizumab) was also tapered a

88 ngly inhibited by an IL-6 receptor antibody (tocilizumab) and less well by TNF-alpha and IL-1beta ant

89 ptor was blocked with a monoclonal antibody (tocilizumab), and signal transducer and activator of tra

90 oquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids.

91 Among these is tocilizumab (anti-IL-6 receptor [IL-6R]) which holds pro

92 Tocilizumab (anti-IL-6R) is approved by the Food and Dru

93 available randomized controlled trial data, tocilizumab appears effective in TNFi failure group, irr

94 ty and mortality associated with SARS-CoV-2, tocilizumab appears to offer benefits in reducing inflam

95 s methotrexate arm vs 19 [18%] of 103 in the tocilizumab arm and 13 [12%] of 108 in the methotrexate

96 r tocilizumab plus placebo-methotrexate (the tocilizumab arm), or methotrexate plus placebo-tocilizum

97 ocilizumab plus methotrexate arm, 103 to the tocilizumab arm, and 108 to the methotrexate arm).

98 lus methotrexate arm, 40 (39%) of 103 in the tocilizumab arm, and 37 (34%) of 108 in the methotrexate

99 egimen, compared with 86 (84%) of 103 in the tocilizumab arm, and 48 (44%) of 108 in the methotrexate

100 lus methotrexate arm, 91 (88%) of 103 in the tocilizumab arm, and 83 (77%) of 108 in the methotrexate

101 Use of tocilizumab as additional treatment with prednisone show

102 of patients receiving 4 mg/kg and 8 mg/kg of tocilizumab as monotherapy, respectively, and by 63% and

103 cluded all patients who used azathioprine or tocilizumab as monotherapy.

104 eous forms of existing therapies (abatacept, tocilizumab), as well as newer-generation monoclonal ant

105 omized to 1 of 7 treatment arms, as follows: tocilizumab at doses of 2 mg/kg, 4 mg/kg, or 8 mg/kg eit

106 in a 2:1:1:1 ratio, to receive subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other

107 to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weig

108 tration-approved Ab antagonist to the IL-6R (tocilizumab) attenuated the severity of influenza A-indu

109 mumab, etanercept, infliximab, rituximab, or tocilizumab before surgery.

110 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%.

111 Tocilizumab combined with any of the DMARDs evaluated wa

112 algia rheumatica despite prednisone therapy, tocilizumab, compared with placebo, resulted in a signif

113 Anti-TNF-a agents and tocilizumab did not differ significantly in terms of rel

114 Anti-TNF-alpha agents and tocilizumab did not differ significantly in terms of rel

115 rapy using the humanized monoclonal antibody tocilizumab directed against the interleukin 6 (IL-6) re

116 , and 6 attacks were associated with reduced tocilizumab dosage (6 vs 8 mg/kg).

117 kly, 14% of those in the group that received tocilizumab every other week, 22% of those in the placeb

118 umab weekly and in 53% of those treated with tocilizumab every other week, as compared with 14% of th

119 ed in one patient in the group that received tocilizumab every other week.

120 inhibitors (TNFi), rituximab, abatacept and tocilizumab, following TNFi failure with no comparative

121 pt and anakinra had failed, was administered tocilizumab for 6 months, and the therapeutic response w

122 ase syndrome (CRS) and the administration of tocilizumab for CRS.

123 were stratified according to the receipt of tocilizumab for cytokine storm and matched to controls u

124 gs merit attention in any clinical trials of tocilizumab for GVHD prevention or treatment and provide

125 current analysis does not support the use of tocilizumab for the management of cytokine storm in pati

126 ed with the IL-6 receptor (IL-6R) antagonist tocilizumab for the treatment of large-vessel vasculitid

127 Tocilizumab generally was well tolerated and no serious

128 ity were assigned to receive 1 of 3 doses of tocilizumab given intravenously every other week for 12

129 izumab group and 18 deaths (27.3%) in the no tocilizumab group (odds ratio, 1.0; 95% confidence inter

130 r edema at 6 months compared to subcutaneous tocilizumab group (odds ratio, 3.96; 95% confidence inte

131 roup and 58% of patients in the subcutaneous tocilizumab group (P = 0.80) had inactive disease and 71

132 Serious infections were more common in the tocilizumab group (seven [16%] of 43 patients) than in t

133 dnan skin score at 24 weeks was -3.92 in the tocilizumab group and -1.22 in the placebo group (differ

134 res mean change at 48 weeks was -6.33 in the tocilizumab group and -2.77 in the placebo group (treatm

135 of normal, occurred in 4% of patients in the tocilizumab group and 1% of those in the control group,

136 reat population included 249 patients in the tocilizumab group and 128 patients in the placebo group;

137 e diseases, three (9%) of 34 patients in the tocilizumab group and 13 (35%) of 37 patients in the aza

138 18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard car

139 At 14 days, 18.0% of the patients in the tocilizumab group and 14.9% of the patients in the place

140 There were 18 deaths (27.3%) in the tocilizumab group and 18 deaths (27.3%) in the no tocili

141 onfidence interval [CI], 8.5 to 16.9) in the tocilizumab group and 19.3% (95% CI, 13.3 to 27.4) in th

142 study were infrequent (4% of patients in the tocilizumab group and 2% of those in the control group).

143 1 adverse event: 15 patients (23%) in the IV tocilizumab group and 21 patients (30%) in the subcutane

144 At 14 days, 24.6% of the patients in the tocilizumab group and 21.2% of the patients in the place

145 ccurred in 38 of 250 patients (15.2%) in the tocilizumab group and 25 of 127 patients (19.7%) in the

146 Eight (14%) of 59 patients in the tocilizumab group and 28 (47%) of 59 patients in the aza

147 gen was 5.0 days (95% CI, 3.8 to 7.6) in the tocilizumab group and 4.9 days (95% CI, 3.8 to 7.8) in t

148 uded in the per-protocol analysis (56 in the tocilizumab group and 52 in the azathioprine group).

149 57 (97%) of 59 patients in the tocilizumab group and 56 (95%) of 59 patients in the aza

150 At 12 months, 63% of patients in the IV tocilizumab group and 58% of patients in the subcutaneou

151 28 occurred in 10.4% of the patients in the tocilizumab group and 8.6% of those in the placebo group

152 One death (2%) occurred in the tocilizumab group and one (2%) in the azathioprine group

153 All patients in the tocilizumab group and two in the standard care group rec

154 ry outcome was the rate of remission in each tocilizumab group as compared with the placebo group tha

155 hazard ratio for intubation or death in the tocilizumab group as compared with the placebo group was

156 ocorticoid-free remission at week 52 in each tocilizumab group as compared with the rate in the place

157 IL-8 increased, while CRP decreased, in the tocilizumab group compared with the placebo group.

158 Seventy-three percent of patients in the tocilizumab group had >or=1 adverse event (AE), compared

159 eases, a lower proportion of patients in the tocilizumab group had a relapse than in the azathioprine

160 as met in significantly more patients in the tocilizumab group than in the placebo group (64 of 75 [8

161 However, the difference was greater in the tocilizumab group than in the placebo group and we found

162 exploratory analyses, fewer patients in the tocilizumab group than in the placebo group had a declin

163 time to first relapse was also longer in the tocilizumab group than the azathioprine group (67.2 week

164 time to the first relapse was longer in the tocilizumab group than the azathioprine group (78.9 week

165 42 (98%) of 43 patients in the tocilizumab group versus 40 (91%) of 44 in the placebo g

166 col analysis, 50 (89%) of 56 patients in the tocilizumab group were relapse-free compared with 29 (56

167 over the 52-week period was 1862 mg in each tocilizumab group, as compared with 3296 mg in the place

168 g 60 infections (2 serious), occurred in the tocilizumab group, as compared with 38, including 15 inf

169 up and 21 patients (30%) in the subcutaneous tocilizumab group.

170 l of 126 patients were randomized (60 to the tocilizumab group; 66 to the control group).

171 At week 52, 80% of the patients who received tocilizumab had at least 70% improvement with no fever,

172 Patients who received tocilizumab had fewer serious infections than patients w

173 Tocilizumab has a well-characterized safety profile.

174 Tocilizumab has been reported to reduce NMOSD disease ac

175 gnaling with the anti-IL-6 receptor antibody tocilizumab has provided some clinical benefit to patien

176 lizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained impro

177 Treatment with tocilizumab in 13 subjects resulted in rapid defervescen

178 tudies are needed to confirm the efficacy of tocilizumab in autoimmune synaptic or presynaptic diseas

179 ind, placebo-controlled, multicenter TOWARD (Tocilizumab in Combination With Traditional DMARD Therap

180 We report on a single-center study of tocilizumab in hospitalized patients with SARS-CoV-2 pne

181 of the anti-interleukin-6 receptor antibody tocilizumab in patients from these populations who are h

182 Here we examined compassionate use of tocilizumab in patients with SARS-CoV-2 pneumonia.

183 neutropenia may limit the maximum dosage of tocilizumab in patients with SLE, the observed clinical

184 his study was lower in patients treated with tocilizumab in the first 2 days of ICU admission compare

185 e {IQR}, 52-71] years), 433 (11.0%) received tocilizumab in the first 2 days of ICU admission.

186 tumor necrosis factor-alpha antagonists and tocilizumab) in patients with Takayasu arteritis.

187 ging lesions were seen in 6 of 8 patients at tocilizumab initiation and in 1 of 8 patients at the las

188 tion in immunosuppression and treatment with tocilizumab, intravenous immunoglobulin, hydroxychloroqu

189 Tocilizumab is a humanized mAb to IL6-receptor-alpha (IL

190 Tocilizumab is a recombinant humanized monoclonal antibo

191 Although the IL-6R antagonist tocilizumab is approved for treatment of CRS, there is n

192 eage expression signature in synovial tissue tocilizumab is more effective than rituximab.

193 Tocilizumab is the first-in-class drug developed to trea

194 Additional doses of tocilizumab may be needed for those showing slow decline

195 ospective nature, these data suggest that IV tocilizumab may result in faster resolution of uveitic m

196 After the switch to tocilizumab (median duration of therapy, 18 months), the

197 of clinical improvement several days later, tocilizumab, methylprednisolone, and therapeutic anticoa

198 Tocilizumab might be effective in NMO, here in a patient

199 are elevated in TRAPS, we hypothesized that tocilizumab might be effective.

200 Tocilizumab might therefore be another safe and effectiv

201 ; IFN-beta-1b SC, n = 41; rituximab, n = 31; tocilizumab, n = 44) and followed during the first 12 mo

202 oaches will overcome the limited efficacy of tocilizumab observed in ovarian cancer to date.

203 g plasma cells, suggest a specific effect of tocilizumab on autoantibody-producing cells.

204 f the interleukin-6 receptor alpha inhibitor tocilizumab on the rates of relapse during glucocorticoi

205 Incubation of HCC cell lines with tocilizumab or knockdown of signal transducer and activa

206 izophrenia to 3 monthly infusions of 8 mg/kg tocilizumab or placebo (normal saline).

207 f the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dos

208 nfliximab (anti-TNF-[Formula: see text]) and tocilizumab or siltuximab (anti-IL-6/IL-6R).

209 ade 1 neurotoxicity, and no patient required tocilizumab or steroids for CAR T-cell-mediated toxiciti

210 assessed in a time-to-event analysis favored tocilizumab over placebo (hazard ratio, 0.55; 95% CI, 0.

211 2.19 [5.65] years; 6945 [82.2%] women), 6369 tocilizumab pairs (mean [SD] age 72.01 [5.46] years; 10

212 ent (ACR20) was significantly greater in the tocilizumab plus DMARD group than in the control group (

213 and hemoglobin levels showed superiority of tocilizumab plus DMARDs over DMARDs alone.

214 randomly assigned patients (1:1:1) to start tocilizumab plus methotrexate (the tocilizumab plus meth

215 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm achieved sustained rem

216 lacebo to active treatments; patients in the tocilizumab plus methotrexate arm switched to standard o

217 ment groups (17 [16%] of 106 patients in the tocilizumab plus methotrexate arm vs 19 [18%] of 103 in

218 to start tocilizumab plus methotrexate (the tocilizumab plus methotrexate arm), or tocilizumab plus

219 7 eligible patients to treatment (106 to the tocilizumab plus methotrexate arm, 103 to the tocilizuma

220 occurring in 38 (36%) of 106 patients in the tocilizumab plus methotrexate arm, 40 (39%) of 103 in th

221 ntire study, 91 (86%) of 106 patients in the tocilizumab plus methotrexate arm, 91 (88%) of 103 in th

222 ssion (RR 1.13, 95% CI 1.00-1.29, p=0.06 for tocilizumab plus methotrexate vs methotrexate, 1.14, 1.0

223 elative risk [RR] 2.00, 95% CI 1.59-2.51 for tocilizumab plus methotrexate vs methotrexate, and 1.86,

224 tocilizumab vs methotrexate, and p=0.59 for tocilizumab plus methotrexate vs tocilizumab).

225 on therapy with either 4 mg/kg or 8 mg/kg of tocilizumab plus MTX (P < 0.05).

226 The findings of this study show that tocilizumab plus MTX results in greater inhibition of jo

227 and 74% of patients receiving those doses of tocilizumab plus MTX, respectively, compared with 41% of

228 eceiving combination therapy with 8 mg/kg of tocilizumab plus MTX.

229 (the tocilizumab plus methotrexate arm), or tocilizumab plus placebo-methotrexate (the tocilizumab a

230 body against interleukin-6 receptor (IL-6R), tocilizumab, prevented M2-differentiation.

231 an urgent need to confirm whether the use of tocilizumab provides a benefit in individuals with COVID

232 Tocilizumab, received weekly or every other week, combin

233 o were not receiving mechanical ventilation, tocilizumab reduced the likelihood of progression to the

234 Interleukin-6 receptor blockade with tocilizumab remains the mainstay pharmacologic therapy f

235 r novel therapies such as ACTH analogues and tocilizumab require additional investigation.

236 ply causality however lack of improvement by tocilizumab requires further clinical trial alterations.

237 Off-label treatment with tocilizumab restored the cytotoxic potential of NK cells

238 ly interrupted with the IL-6Ralpha inhibitor tocilizumab, sensitizing cells to anoikis in vitro and r

239 The efficacy and safety of tocilizumab should be investigated in a phase 3 trial be

240 systemic symptoms, while the IL-6 inhibitor tocilizumab shows great potential.

241 Tocilizumab significantly reduced the risk of a subseque

242 icted and analyzed the responses of HNSCC to tocilizumab (TCZ) and cisplatin combination therapy.

243 syndrome, the blockade of its receptor with tocilizumab (TCZ) could reduce mortality and/or morbidit

244 We recently reported on clinical use of tocilizumab (TCZ) for treatment of cAMR in HLA-sensitize

245 Anti-human IL-6Ralpha blockade by tocilizumab (TCZ) has been used in pig-to-baboon organ x

246 is study assessed the efficacy and safety of tocilizumab (TCZ) in refractory CME.

247 s to retrospectively analyze the efficacy of tocilizumab (TCZ) in treating corticosteroid (CS)-refrac

248 Herein, an antirheumatic targeted drug tocilizumab (TCZ) is conjugated to polymer nanoparticles

249 erent doses of intravenous (IV) infusions of tocilizumab (TCZ), an IL-6 inhibitor, in eyes with nonin

250 ing a novel drug (anti-IL-6 receptor (IL-6R),Tocilizumab [TCZ]) + intravenous Ig (IVIg) to assess saf

251 ssion were higher in those receiving 8 mg/kg tocilizumab than in those receiving placebo (P < 0.0001

252 cilizumab arm), or methotrexate plus placebo-tocilizumab (the methotrexate arm).

253 majority of patients who received 8 mg/kg of tocilizumab, the C-reactive protein level/erythrocyte se

254 of resolution [logMAR]) were recorded during tocilizumab therapy at months 1, 3, 6, and 12.

255 Specific targeting of IL-6 using tocilizumab therapy in patients with rheumatoid arthriti

256 Reinitiation of tocilizumab therapy led to good uveitis control and ME r

257 Prolonged tocilizumab therapy may be safe and effective from early

258 rquartile range, 3.0-5.0) in the year before tocilizumab therapy to 0.4 (interquartile range, 0.0-0.8

259 Mean follow-up with tocilizumab therapy was 15.2 months (range, 12-18 months

260 Tocilizumab therapy was withdrawn in 2 patients because

261 Before tocilizumab therapy, conventional immunosuppressive ther

262 mong kidney transplant patients treated with tocilizumab, there was no excess risk of infections comp

263 idence rate of infections was observed among tocilizumab-treated compared with IVIG/rituximab-treated

264 ed adverse events occurred in 36 (61%) of 59 tocilizumab-treated patients and 49 (83%) of 59 azathiop

265 ifference in 28-day case fatality rate among tocilizumab-treated patients with versus without superin

266 The rationale for tocilizumab treatment is supported by detection of IL-6

267 Tocilizumab treatment led to dosage-related decreases in

268 During tocilizumab treatment, the median annualized relapse rat

269 One patient died in relation to tocilizumab treatment.

270 evels (P = .02) dropped significantly during tocilizumab treatment.

271 Three patients remained relapse free during tocilizumab treatment.

272 )-6 was the predominant cytokine detected at tocilizumab treatment.

273 -reactive protein (CRP) levels pre- and post-tocilizumab treatment.

274 Off-label tocilizumab use in COVID-19 patients reflects concern fo

275 methotrexate, 1.14, 1.01-1.29, p=0.0356 for tocilizumab vs methotrexate, and p=0.59 for tocilizumab

276 ate vs methotrexate, and 1.86, 1.48-2.32 for tocilizumab vs methotrexate, p<0.0001 for both compariso

277 Tocilizumab was administered to 56 patients (41%) with C

278 events, and a shorter time from CRS onset to tocilizumab was associated with a lower rate of CV event

279 Although tocilizumab was associated with an increased proportion

280 Organization (WHO) meta-analysis found that tocilizumab was associated with reduced mortality in hos

281 The safety profile of tocilizumab was consistent with the profiles in previous

282 evere; cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and

283 In this study, tocilizumab was effective in the treatment of refractory

284 Tocilizumab was efficacious in severe, persistent system

285 Tocilizumab was given at 8 mg/kg intravenously every 4 w

286 Tocilizumab was mostly well tolerated, with a safety pro

287 Tocilizumab was not associated with a significant reduct

288 Tocilizumab was not effective for preventing intubation

289 d and stopped, then tocilizumab (and placebo-tocilizumab) was also tapered and stopped.

290 occurred in 56% of the patients treated with tocilizumab weekly and in 53% of those treated with toci

291 % of the patients in the group that received tocilizumab weekly, 14% of those in the group that recei

292 possible, and sample sizes for rituximab and tocilizumab were small.

293 tonavir, hydroxychloroquine, remdesivir, and tocilizumab) were associated with peak hospitalization l

294 r (infliximab), and interleukin-6 inhibitor (tocilizumab) were either negative (abatacept) or were as

295 (anti-CD20), which reduces inflammation, and tocilizumab, which potentially benefits both of these pa

296 is managed with the IL-6 receptor antagonist tocilizumab with or without corticosteroids, with questi

297 ukin-6 receptor-blocking monoclonal antibody tocilizumab with or without methotrexate (a conventional

298 stained remission by immediate initiation of tocilizumab with or without methotrexate are more effect

299 In both patients, ME relapsed 3 months after tocilizumab withdrawal.

300 s to test whether an IL-6 receptor antibody, tocilizumab, would improve residual positive and negativ